![Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - The Lancet Diabetes & Endocrinology Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/e1f51155-083e-4b9c-a610-b644a7d7168b/gr1.gif)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - The Lancet Diabetes & Endocrinology
![Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11 | SpringerLink Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11 | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13300-021-01140-9/MediaObjects/13300_2021_1140_Fig1_HTML.png)
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11 | SpringerLink
![Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes Louis Kuritzky, MD1; Guillermo Umpierrez, - ppt video online download Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes Louis Kuritzky, MD1; Guillermo Umpierrez, - ppt video online download](https://slideplayer.com/slide/4129970/13/images/27/Single-Dose+Pen%2A+It+contains+a+single+dose+of+the+ready+to+use+dulaglutide+solution..jpg)
Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes Louis Kuritzky, MD1; Guillermo Umpierrez, - ppt video online download
![Patient-reported outcomes in patients with type 2 diabetes treated with investigational dulaglutide doses added to metformin (AWARD-11) - Media Centre | EASD Patient-reported outcomes in patients with type 2 diabetes treated with investigational dulaglutide doses added to metformin (AWARD-11) - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/939_251765_1/Slide1.jpg)